ClinicalTrials.gg

Alzheimer Disease clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,972 studies for Alzheimer Disease across more than 10 countries. 932 are recruiting or about to start. 3,078 of them are mainly about Alzheimer Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 4,344 studies for Alzheimer Disease. How that becomes 3,968 here

This page counts the studies the registry files under Alzheimer Disease, and those it files under no condition that list Alzheimer Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 4,344Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −77List Alzheimer Disease as a condition, but the registry did not file them under itMost often written as “Alzheimer s Disease” (17), “Mild Alzheimer's Disease” (8), and “Prodromal Alzheimer's Disease” (7). The registry filed them under other conditions only, most often Cognitive Dysfunction (29) and Dementia (15).
  3. −299Match it another way188 name it in the title, 17 in a keyword, and 94 by a synonym or other text the search reads.
  4. 3,968The count on this page79 of them list Alzheimer Disease in their own words; the registry filed them under no condition.

Status

Completed
2,141
Recruiting
643
Status unknown
325
Terminated
301
Not yet recruiting
213
Active, not recruiting
165

Phase

Phase 2
730
Phase 1
575
Phase 3
359
Phase 4
139
Early Phase 1
63

Where

United States
1,942
France
438
Canada
321
Spain
278
United Kingdom
261
China
260

Who develops what

Add Alzheimer Disease to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 80 programs from 62 companies, 74 with this as their studies’ main aim; 16 with a live phase 3 study; 13 primary completions in the next 12 months. Compare Bristol-Myers Squibb, Eli Lilly and Hoffmann-La Roche here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DonepezilRecent, repeated
Evidence
  • NCT07066826 · Wanbangde Pharmaceutical Group Co., LTD · Phase 3 · live · comparator · “Donepezil hydrochloride tablets” · registered Jul 2025
  • NCT05811000 · Mediforum Ltd., Co. · Phase 3 · comparator · “Donepezil” · registered Mar 2023
  • NCT05345509 · Inventage Lab., Inc. · Phase 2 · live · comparator · “Aricept Tablet” · registered Apr 2022
  • NCT03055741 · Daehwa Pharmaceutical Co., Ltd. · Phase 2 · background · “Donepezil” · registered Feb 2017
  • NCT02580305 · Suven Life Sciences Limited · Phase 2 · background · “Donepezil” · registered Oct 2015
Eisai Co., Ltd.47% of its industry studiesUS: off-patent, 17 generics marketed33 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
xanomelinePhase 4 trial recorded☆ Track10 live phase-3 studies: NCT06976216, NCT06976203, NCT05980949Bristol-Myers Squibb
trospiumPhase 4 trial recorded☆ Track8 live phase-3 studies: NCT06976216, NCT06976203, NCT05980949Bristol-Myers Squibb
florzolotau F-18☆ Track2 live phase-3 studies: NCT07752784, NCT07422857JYAMS PET Research & Development Limited
dmbi☆ Track1 live phase-3 study: NCT07251023Bigespas LTD
donanemabApproved: US 2024 · EU 2025☆ Track5 live phase-3 studies: NCT07602582, NCT05508789, NCT04437511Eli Lilly and Company

The 5 in phase 3 with the nearest primary completion, of 80 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (13)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 24 Nov 2026 est.xanomeline, trospium · Bristol-Myers Squibb · Phase 3 main aimNCT06585787 A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) — primary endpoint: Change from baseline in Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) score · 406 enrolled
  • 1 Dec 2026 est.florzolotau F-18 · JYAMS PET Research & Development Limited · Phase 3 main aimNCT07422857 Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function — primary endpoint: Evaluate the effectiveness of visual reading results of [18 F]-APN-1607 injection PET imaging in detecting tau NFTs(Neurofibrillary Tangles) · 316 enrolled
  • 9 Dec 2026 est.xanomeline, trospium · Bristol-Myers Squibb · Phase 3 main aimNCT06126224 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) — primary endpoint: Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) score · 500 enrolled

10 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Alzheimer Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimuscarinics 7 open · Cholinesterase inhibitors 4 open · GLP-1 receptor agonists 4 open · Stimulants 3 open · Reverse transcriptase inhibitors 2 open

Coming up

343studies finish main data collection within a year12 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger. 34 (5%) take children under 18. 9 (1%) are for women only and 3 (<1%) for men only; 285 (44%) take healthy volunteers.

Recruiting studies that take each age, of 643
AgeWomenMen
1030 (5%)30 (5%)
18199 (31%)193 (30%)
30221 (34%)216 (34%)
40266 (41%)260 (40%)
50424 (66%)419 (65%)
65623 (97%)617 (96%)
75609 (95%)604 (94%)
85517 (80%)511 (79%)

Across all 3,972 studies, recruiting or not: 10% stop at 75 or younger and 6% at 65; 7% take children; 1% are for women only and 2% for men only; 37% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Alzheimer Disease studies take

Of 258 phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 37 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 117 mo7–39 · 234 studies12 mo5–23 · 161 studies44 mo18–57 · 73 studies
Phase 1/245 mo21–63 · 62 studies—41 mo21–63 · 35 studies
Phase 237 mo21–58 · 258 studies26 mo17–39 · 131 studies54 mo37–69 · 127 studies
Phase 2/352 mo33–59 · 28 studies——
Phase 347 mo28–73 · 101 studies42 mo28–61 · 75 studies—
Phase 447 mo27–67 · 41 studies——
Interventional, no phase29 mo15–51 · 962 studies18 mo11–40 · 77 studies30 mo15–51 · 885 studies
Observational67 mo35–171 · 405 studies34 mo20–63 · 41 studies81 mo39–203 · 364 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Newly registered25

Show 20 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,972. Browse all 3,972 → or search them.